Profile of Prescribing COVID -19 Drug Therapy in Inpatients At Jakarta Haji Hospital

Main Article Content

harpolia cartika
Harpolia Cartika
Yusmaniar Yusmaniar
Adin Hakim Kurniawan
Fatwa Hasbi
Desi Suryani

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-nCoV-2) the cause of Coronavirus Disease 2019 (COVID-19) was first discovered in Wuhan on December 2019, has spread throughout the world. Each country tries to develop treatment protocol guidelines following the latest research developments to increase the cure rate due to the absence of standard guidelines.The purpose of this research is to knowing the profile of prescribing COVID-19 drug therapy in inpatients at jakarta haji hospital the period September 2020-February 2021. This research is non-experimental with quantitative descriptive study design was taken retrospectively using secondary data in the form of prescription data history of COVID-19 patient visits recorded on the system with sampling techniques that is total sampling. The results showed that in total 387 COVID-19 patients the most were 46-65 years oldwith 198 patients and the mostly malewith 212 patients. The longest duration of treatment was 3-10 days as many as 246 patients and the highest degree of disease was mild to moderate as many as 363 patients The most widely prescribed drugs were Paracetamol (84.37%), Dexamethasone (78.4%), Osetalmivir (74.1%), Heparin (67.81%), Alprazolam (60.27%), Acetylsitein (58 ,12%), Insulin (54.93%), CTM (53.13%), Amlodipine 50.43%, Vitamin C (48.04%), Levofloxacin (35.48%), and Omeprazole (31.98 %). COVID-19 patients at the Jakarta Haji Hospital receive the main therapies, namely vitamins, antibiotics, antivirals, respiratory drugs, gastrointestinal drugs. The suitability of prescribing drug therapy classes based on the guidelines for the management of COVID-19 is 83% and those that are not in accordance with the guidelines are 27%.

Article Details

How to Cite
1.
cartika harpolia, Cartika H, Yusmaniar Y, Hakim Kurniawan A, Hasbi F, Suryani D. Profile of Prescribing COVID -19 Drug Therapy in Inpatients At Jakarta Haji Hospital. SANITAS [Internet]. 21Jun.2022 [cited 27Jun.2022];13(1):1-2. Available from: https://sanitas.e-journal.id/index.php/SANITAS/article/view/20220601-cartika
Section
Full Research Article

References

Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian dengan Penyakit Komorbid COVID-19. Keperawatan Silampari. 2020 Oct 11;4:48–55.

Ilpaj SM, Nurwati N. Analisis Pengaruh Tingkat Kematian Akibat COVID-19 Terhadap Kesehatan Mental Masyarakat di Indonesia. Focus : Jurnal Pekerjaan Sosial. 2020 Aug 4;3(1):16.

Apt. A. The Impact of Community Behavior on the Prevention of Coronavirus Disease 19 Transmission : Literature Review. SANITAS. 2021 Aug 5;12(Public Health):73–85.

Irsal M. Preparedness Radiological Services for the COVID-19 Emergency Hospital in Wisma Atlet Kemayoran. SANITAS. 2021 Jul 21;12(Radiation Therapy):21–35.

Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. Journal of Medical Virology. 2020 Jun 1;92(6):639–44.

Dwi Nugroho W, Indah WC, Istiqomah N, Cahyasari I, Indrastuti M, Sugondo P, et al. Literature Review : Transmisi Covid-19 dari Manusia ke Manusia Di Asia. Vol. 2, Jurnal of Bionursing. 2020.

Tandra H. Virus Corona Baru COVID-19. Yogyakarta: Rapha Publishing;

Badan Pengawas Obat dan Makanan. Informatorium Obat COVID-19 di Indonesia Edisi 2. 2nd ed. Badan Pengawas Obat dan Makanan Republik Indonesia; 2020.

Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang C bin, Bernardini S. The COVID-19 pandemic. Critical Reviews in Clinical Laboratory Sciences. Taylor and Francis Ltd.; 2020. p. 365–88.

SatgasCovid-19. Peta Sebaran COVID-19 | Covid19.go.id [Internet]. [cited 2022 Mar 31]. Available from: https://covid19.go.id/peta-sebaran-covid19

Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. Pedoman Tatalaksana COVID-19 Edisi 3 Tim Editor Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 2020.

Badan Pengawas Obat Dan Makanan Republik Indonesia. Informatorium Obat COVID-19 di Indonesia. 2020.

SatgasCovid-19. Covid-19 [Internet]. [cited 2022 Mar 31]. Available from: https://corona.jakarta.go.id/id/zona-pengendalian-rt

Hidayati D. Jurnal Kependudukan Indonesia | Edisi Khusus Demografi dan COVID-19. 2020.

Penelitian A, Kebijakan Kesehatan Indonesia J, Hadumaon Siagian T. Mencari Kelompok Berisiko Tinggi Terinfeksi Virus Corona dengan Discourse Network Analysis Finding High Risk Groups to Corona Virus Using Discourse Network Analysis. 2020 Jun.

KEMENKES PADK [Internet]. [cited 2022 Mar 31]. Available from: http://padk.kemkes.go.id/article/read/2020/04/23/21/hindari-lansia-dari-covid-19.html?msclkid=18497860b08611ecaca1d14146035f1b

Siagian TH. Mencari Kelompok Berisiko Tinggi Terinfeksi Virus Corona dengan Discourse Network Analysis. Jurnal Kebijakan Kesehatan Indonesia. 2020;09(02):98–106.

Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Carl CA, et al. COVID-19 length of hospital stay: A systematic review and data synthesis. BMC Medicine. 2020;18(1).

Moretto F, Sixt T, Devilliers H, Abdallahoui M, Eberl I, Rogier T, et al. Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19? International Journal of Infectious Diseases. 2021;105:256–60.

Paluseri, A. F, Zulfahmidah, Oktaviani R. Analisis Efektivitas Biaya Penggunaan Antibiotik Levofloksasin dan Azitromisin pada Pasien Penderita CORONA VIRUS DISEASE-2019. 2021;XVII(1).

Karampela I, Dalamaga M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Archives of Medical Research. 2020;51(7):741–2.

Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. Journal of Infection and Public Health. 2021;14(5):570–6.

Lukito JI. Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286. 2020;47(5).

Faradiba N. Perbedaan Oseltamivir dan Favipiravir untuk Mengobati Covid-19 [Internet]. 2021 [cited 2022 Mar 31]. Available from: https://www.kompas.com/sains/read/2021/07/04/110100923/perbedaan-oseltamivir-dan-favipiravir-untuk-mengobati-covid-19

Laksono RM, Musba AT, Susila D, Tanra AH. Pain Management Recommendation for Indonesian COVID-19 Patients by Indonesian Society of Anesthesiology for Pain Management (ISAPM). Asian Journal of Anesthesiology 2021 1 Asian Journal of Anesthesiology. 2021;(2):1–7.

Sestili P, Fimognari C. Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness? Frontiers in Pharmacology. 2020;11(October):1–7.

Pratiwi WR. Drugs repurposing for COVID-19: phase III clinical trial evaluation. Indonesian Journal of Pharmacology and Therapy. 2021;2(1):35–49.

Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384(8):693–704.

Willim HA HA, Supit A. Koagulopati pada Corona Virus Disease - 2019 (COVID-19) : Tinjauan Pustaka. Intisari Sains Medis. 2020;11:749–56.

Eko Nugroho T. Penggunaan Heparin Dosis Tinggi pada Pasien COVID-19 dengan ARDS dan Hipertensi di Unit Perawatan Intensif (ICU) Use of High-Dose Heparin in COVID-19 Patients with ARDS and Hypertension in the Intensive Care Unit (ICU). Vol. 12, Jurnal Anestesiologi Indonesia. 2020.

Faurin M, Fauzar F, Kurniati R, Kam A, Decroli E. COVID-19 dengan Komorbid Tuberkulosis Paru dan Diabetes Melitus. Jurnal Ilmu Kesehatan Indonesia [Internet]. 2020 May 24 [cited 2022 Mar 31];1(3):445–9. Available from: http://jikesi.fk.unand.ac.id/index.php/jikesi/article/view/466

Aguila EJT, Cua IHY. Repurposed GI Drugs in the Treatment of COVID-19. Vol. 65, Digestive Diseases and Sciences. 2020. p. 2452–3.

Ray A, Sharma S, Sadasivam B. The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences. Drug Research. 2020;70(10):484–8.

Torres J, Go CC, Chohan F, L GC, Sanchez-gonzalez MA. Chlorpheniramine Maleate Nasal Spray In COVID-19 Patients : Case Series. :9–11.

Jannah RJ, Jatimi A, Azizah MJ, Munir Z, Rahman HF. Kecemasan Pasien COVID-19: A Systematic Review. Jurnal Penelitian Kesehatan Suara Forikes. 2020;11(2):33–7.

Kemenkes RI. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI Tahun 2020. Direktorat Pencegahan Dan Pengendalian Masalah Kesehatan Jiwa Dan Napza, Direktorat Jenderal Pencegahan Dan Pengendalian Penyakit, Kementerian Kesehatan RI. 2020. 1–64 p.

Zhang LK, Sun Y, Zeng H, Wang Q, Jiang X, Shang WJ, et al. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discovery. 2020;6(1):1–34.

Burhan, Erlina,. Susanto, D A,. Nasution, S A. et al, editor. Protokol Tatalaksana Covid-19. PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2020.